Table 3.
The demographic and comorbid medical disorders at index date after propensity score weighting among hypertensive and diabetic patients who were prescribed with either angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) stratified by chronic kidney disease or not
| Propensity score weighting | ||||||
|---|---|---|---|---|---|---|
| With CKD | Without CKD | |||||
| ACEi (n = 932) | ARB (n = 2135) | Standardized mean difference | ACEi (n = 5966) | ARB (n = 10,623) | Standardized mean difference | |
| Duration from DM to index date (years) | 3.50 ± 3.33 | 3.52 ± 2.09 | −0.0049 | 3.00 ± 3.11 | 3.01 ± 2.29 | −0.0035 |
| Age (years) (mean ± SD) | 65.5 ± 13.3 | 65.2 ± 8.8 | 0.0276 | 60.8 ± 12.9 | 60.6 ± 9.8 | 0.0175 |
| Age group (years) | 0.0123 | 0.0049 | ||||
| 20–49 (%) | 14.70 | 15.06 | 21.81 | 21.92 | ||
| 50–64 (%) | 32.08 | 32.25 | 40.56 | 40.69 | ||
| 65+ (%) | 53.22 | 52.69 | 37.63 | 37.39 | ||
| Male sex | 59.12 % | 59.21 % | −0.0019 | 59.52 % | 59.62 % | −0.0019 |
| Congestive heart failure | 8.05 % | 8.15 % | −0.0039 | 3.96 % | 3.94 % | 0.0006 |
| Stroke | 16.20 % | 16.15 % | 0.0014 | 12.19 % | 12.16 % | 0.0007 |
| Malignant dysrhythmia | 0.21 % | 0.21 % | 0.0014 | 0.49 % | 0.48 % | 0.0011 |
| Cardiogenic shock | 0.64 % | 0.73 % | −0.0102 | 0.27 % | 0.27 % | −0.0011 |
| MI/PCI | 5.15 % | 5.08 % | 0.0030 | 4.98 % | 4.96 % | 0.0008 |
| CABG | 0.11 % | 0.11 % | −0.0010 | 0.52 % | 0.51 % | 0.0008 |
| Thrombolysis therapy | 0.00 % | 0.00 % | −0.0002 | 0.28 % | 0.28 % | 0.0012 |
| Hyperlipidemia | 59.44 % | 59.86 % | −0.0085 | 53.77 % | 53.77 % | −0.0017 |
| Incidence of ESRDa | 1.39 | 2.34 | 0.30 | 0.37 | ||
| (95 % CI) | (1.00−1.78) | (1.80−2.89) | (0.23−0.37) | (0.29−0.46) | ||
DM diabetes mellitus, ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, CKD chronic kidney diseases, MI myocardial infarction, PCI percutaneous coronary intevention, CABG coronary artery bypass graft surgery
aIncidence per 100 person-years